Lori Kunkel

Dr. Lori A. Kunkel, MD, is an Independent Director at Enliven Therapeutics, Inc., an Independent Director at Oric Pharmaceuticals, Inc., an Independent Director at K36 Therapeutics, Inc. and an Owner at Lak505, LLC.
She is on the Board of Directors at Enliven Therapeutics, Inc., Oric Pharmaceuticals, Inc. and K36 Therapeutics, Inc. Dr. Kunkel was previously employed as an Independent Director by Nurix Therapeutics, Inc., an Independent Director by Curis, Inc., a Chief Medical Officer by Pharmacyclics, Inc., a Chief Medical Officer by ACT Biotech, Inc., a Chief Medical Officer by Syndax Pharmaceuticals, Inc., a Chief Medical Officer by Proteolix, Inc., a Vice President-Clinical Development by Xencor, Inc., a Vice President-Medical Affairs by Genitope Corp., a Head-Clinical Scientist by Genentech, Inc., an Associate Director-Clinical Development by Chiron Corp., a Principal by DNAX Research, Inc., a Principal by Onyx Pharmaceuticals, Inc., a Principal by Salmedix, Inc., a Member-Bone Marrow Transplant Unit by University of California, a Principal by XOMA Royalty Corp., and a Principal by ZymoGenetics, Inc. She also served on the board at Tocagen, Inc., Harpoon Therapeutics, Inc., Maverick Therapeutics, Inc., Loxo Oncology, Inc. and Amphivena Therapeutics, Inc. She received her undergraduate degree from the University of California San Diego and a doctorate degree from the University of Southern California.